CLINICAL INVESTIGATIONS

Transcription

1 CLINICAL INVESTIGATIONS 305 : The Impact of Myocardial Revascularization After Acute Coronary Syndromes on One-Year Cardiovascular Mortality Dalia Lukšienė 1, Irena Milvidaitė 1, 2, Rimvydas Šlapikas 2, Gediminas Jaruševičius 2, Adakrius Siudikas 3, Jonė Venclovienė 1, Remigijus Žaliūnas 2 1 Institute of Cardiology, Medical Academy, Lithuanian University of Health Sciences, 2 Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, 1 Department of Cardiac, Thoracic, and Vascular Surgery, Medical Academy, Lithuanian University of Health Sciences, Lithuania Key words: acute coronary syndromes; myocardial revascularization; one-year cardiovascular mortality. Summary. The aim of this observational study was to evaluate the impact of myocardial revascularization performed after acute coronary syndromes on one-year cardiovascular mortality. Material and Methods. The study population comprised 1226 consecutive patients who were admitted to the Clinic of Cardiology in 2005 because of acute coronary syndromes with significant ( 70%) coronary artery stenoses. The relationship between myocardial revascularization and oneyear cardiovascular mortality was evaluated by applying multivariable logistic regression. Cardiovascular mortality was evaluated using the Kaplan-Meier method. Results. Of all the patients included into the study, 540 had Q-wave myocardial infarction, 339 patients had non Q-wave myocardial infarction, and 347 patients were treated for unstable angina pectoris. During hospitalization, 496 patients underwent percutaneous transluminal coronary angioplasty, 373 patients underwent coronary artery bypass grafting within 60 days following acute coronary syndromes, and 357 patients received pharmacological treatment alone. During one-year follow-up, 105 cases of cardiovascular death were registered. The one-year cardiovascular mortality was significantly lower in patients who underwent percutaneous transluminal coronary angioplasty or coronary artery bypass grafting comparing with those patients who received only pharmacotherapy (5.4% and 7.8% vs. 14.3%, P<0.05). Multivariate logistic regression analysis revealed that myocardial revascularization independently reduced one-year cardiovascular mortality (adjusted odds ratio for percutaneous transluminal coronary angioplasty, 0.304; 95% CI, 0.18 to 0.53; P, and coronary artery bypass grafting, 0.540; 95% CI, 0.32 to 0.90; P=0.018) in patients who were admitted because of acute coronary syndromes. Conclusions. Myocardial revascularization performed after acute coronary syndromes was significantly associated with the reduction of cardiovascular mortality within one-year period independently of clinical variables. Introduction During the last decades, myocardial revascularization (MR) applied in cases of acute coronary syndromes (ACSs) has significantly reduced cardiovascular mortality during in-hospital period compared with those receiving only pharmacological treatment. Data comparing the impact of pharmacotherapy and MR on cardiovascular mortality during the posthospitalization in patients with ACSs are scarce and inconclusive. It has been reported that early invasive treatment in patients with ST-segment elevation myocardial infarction (MI) reduces mortality not only during in-hospital period, but also later, while in those with non Q-wave ACSs, the positive impact of MR during one year after ACSs was observed only in high-risk patients (1 5). The aim of our observation study was to evaluate the impact of MR performed after ACSs on cardiovascular mortality within one-year period. Material and Methods The study population comprised 1226 consecutive patients with significant ( 70%) coronary artery (CA) stenoses, admitted to the Clinic of Cardiology, Hospital of Lithuanian University of Health Sciences (former Kaunas University of Medicine) because Correspondence to I. Milvidaitė, Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Eivenių 2, Kaunas, Lithuania irena.milvidaite@kaunoklinikos.lt Adresas susirašinėti: I. Milvidaitė, LSMU MA Kardiologijos klinika, Eivenių 2, Kaunas El. paštas: irena.milvidaite@kaunoklinikos.lt

2 306 Dalia Lukšienė, Irena Milvidaitė, Rimvydas Šlapikas, et al. of ACSs. After one year, survival data of 1222 patients (99.7%) were collected. The evaluation of patients condition was performed using the data from the database of the Heart Center covering the period of hospitalization, and the obtained information was verified using the patients case histories. Demographic and clinical characteristics, selected laboratory findings, cardiac medications and procedures, cardiovascular events, and outcomes were recorded on a standardized case report form by a study coordinator. The final discharge diagnosis was made by the attending physician using one of the following categories: Q-wave MI, non Q-wave MI, and unstable angina pectoris (UAP). The course and outcomes of the disease during one year were evaluated using the patients records taken from the outpatient unit of the Department of Cardiology, data of the standardized questionnaire (postal or via phone), and information from the Residents Register Service under the Ministry of the Interior and the Civil Registry Office of Kaunas city. In case of hospitalization, new data were gathered by a systematic review of the patients discharge lists. Data on patient s status and used medications were recorded on the standardized case report form. Information on procedures, including percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG), accomplished during the follow-up was collected. Myocardial infarction was diagnosed based on angina pain and its equivalents, markers of ischemic damage on ECG (new-onset Q wave, ST-segment and T-wave alterations), and an increase of more than 0.2 μg/l in troponin I levels. The diagnosis of UAP was confirmed in the presence of the angina syndrome and ischemic changes on ECG without an increase in blood levels of troponin I. The degree of acute heart failure (HF) was evaluated according to the Killip classification, and renal failure was considered as significant when the peak creatinine clearance was <60 ml/min. During inpatient treatment, echocardiography was performed and echocardiographic findings were assessed according to the guidelines of the American Society of Echocardiography and the European Association of Echocardiography (2005). The European System for Cardiac Operative Risk Evaluation (EuroSCORE) was used to assess patients status, and risk was defined as high when score was more than 6. Myocardial revascularization included successful (TIMI 3) PTCA performed during the inpatient period and CABG provided at the time of ACS and performed within 60 days from an acute MI episode. If the patient underwent PTCA during the early period and later CABG, the effectiveness of the latter procedure was evaluated. The death registered during the period of one year following ACSs was defined as cardiovascular when the cause of death was one of MI complications (heart rupture, arrhythmias, conductional disorders, or acute HF), chronic HF, or stroke or when death occurred suddenly within the first 6 hours from the onset of symptoms during the posthospitalization period. Statistical Analysis. Statistical analysis was carried out with the SPSS statistical software for Windows, version The comparison of continuous variables between groups was done using the Student t test. The Pearson chi-square test was used to evaluate differences for categorized variables. Logistic regression analysis was performed to relate power of MR to cardiovascular mortality during one year. Unadjusted odds ratio (OR) with 95% confidence intervals was used to measure crude associations between the predictive variable and cardiovascular mortality. Age, previous MI, previous myocardial revascularization, arterial hypertension, Q-wave MI, Killip class, renal failure, paroxysmal atrial fibrillation, ventricular fibrillation, mitral insufficiency of second or higher degree, left ventricular ejection fraction (LVEF), number of diseased coronary vessels, peripheral artery disease, and previous stroke were included as confounding variables in multivariate models. Adjusted OR and 95% confidence intervals were calculated for each independent variable. Patient survival was evaluated using the Kaplan-Meier method. Survival curves were compared using a log-rank test; the difference was considered statistically significant if P<0.05. Results Among 1226 patients with ACSs, 540 had Q- wave MI and 686 ACSs (339 had non Q-wave MI and 347 had UAP). Invasive treatment was applied in 81.1% of patients with Q-wave MI and in 62.8% of patients with non Q-wave ACSs (Table 1). In case of Q-wave MI, PTCA was applied more frequently than CABG; in the presence of UAP, CABG was performed more commonly; and in case of non Q-wave MI, both methods were applied in similar numbers of patients. In patients with Q-wave Table 1. Rate of the Application of Invasive Inpatient Treatment in Different Acute Coronary Syndromes Treatment PTCA CABG Pharmacotherapy alone Q-wave MI (n=540) Non Q-wave ACSs (n=686) Values are percentage. MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting; ACS, acute coronary syndrome.

3 The Impact of Myocardial Revascularization on Cardiovascular Mortality 307 MI, in 79.5% of cases, PTCA was performed within the first 12 hours; in 2.9% of cases, CABG was performed within the first day; and in patients with non Q-wave ACS, in 20.6% of cases, MR was performed within the first 3 days. In total, invasive treatment was applied in 869 patients (70.9%): 496 patients underwent PTCA; 35, PTCA and CABG; 338, CABG; 357 patients (29.1%) received pharmacological treatment alone. Stents were implanted in 204 patients (41.1%) during PTCA. Clinical characteristics of patients with ACSs who underwent myocardial MR during the inpatient period and those who received pharmacotherapy alone were compared (Table 2). There were no age differences between patients who underwent MR during hospitalization and those who received only pharmacologic treatment; more than half of the patients were men. Patients who received pharmacotherapy alone significantly more frequently had previously experienced MI, more frequently had previously undergone MR, and more frequently had arterial hypertension, diabetes mellitus, peripheral artery disease, or stroke. Their clinical condition during the hospitalization was more severe, i.e., they more frequently had Killip class 3 4, paroxysmal atrial fibrillation, LVEF of <40%, eccentric LV hypertrophy, creatinine clearance of <60 ml/min, and EuroSCORE of more than 6. The patients who underwent MR more frequently had Q-wave MI and blood level of troponin I >10 μg/l as compared with the patients who received pharmacotherapy alone. More than half of the patients in both groups were at high operative risk. During hospitalization, all patients received standard treatment with nitrates, heparin, betaadrenoreceptor blockers, angiotensin-converting enzyme inhibitors, antiplatelet agents, and statins. Data on medication use at 1 year were gathered for 1004 survivors (in 17.8% of cases, data were unavailable). Table 3 presents the comparison of medication usage between the different treatment strategy groups during 1 year after acute coronary syndromes. There were no significant differences in medication usage and performed PTCA rate between the groups (4.2% and 3.5%), but CABG was performed more frequently in patients who received pharma- Treatment Strategy Clinical Variable Pharmacotherapy N=357 Myocardial Revascularization N=869 P Men >0.05 Age, mean (SD), years 64.4 (10.7) 65.6 (11.3) >0.05 Previous MI Previous PTCA Previous CABG Previous stroke <0.05 Arterial hypertension Diabetes mellitus <0.05 Peripheral artery disease <0.01 Q-wave MI Non Q-wave MI >0.05 Unstable angina pectoris Acute heart failure: Killip class 2 Killip class >0.05 Paroxysmal atrial fibrillation <0.05 Ventricular fibrillation >0.05 Paroxysmal ventricular tachycardia CA stenosis 70%: one two three Table 2. Clinical Characteristics of Patients With Acute Coronary Syndromes by the Treatment Strategy Applied During the Acute Period >0.05 >0.05 >0.05 Troponin I >10 μg/l Estimated glomerular filtration rate <60 ml/min LVEF <40% <0.05 Mitral insufficiency >0.05 EuroSCORE > <0.01 Values are percentage except where noted. MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction; CA, coronary artery.

4 308 Dalia Lukšienė, Irena Milvidaitė, Rimvydas Šlapikas, et al. Table 3. Treatment of the Surviving Patients During the First Year After Acute Coronary Syndromes Treatment During One Year Treatment Strategy Pharmacotherapy (n=278) Revascularization (n=726) Beta-adrenoreceptor blockers >0.05 Aspirin >0.05 Clopidogrel >0.05 ACE inhibitors >0.05 Statins >0.05 PTCA >0.05 CABG Values are percentage. ACE, angiotensin-converting enzyme; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting. cotherapy than those who underwent revascularization (8.7% and 2.5%, respectively) (P). During the inpatient period, cardiovascular death occurred in 61 patients (5.0%). Cardiovascular death occurred in 42 (7.8%) of the 540 patients with Q-wave MI and in 19 (2.8%) of the 686 patients with non Q-wave ACS (P). During the hospitalization, cardiovascular mortality was significantly lower in patients with Q-wave MI who underwent MR as compared with patients treated with medications only (5.7% and 16.7% of patients, respectively; P); there was no significant difference in cardiovascular mortality among patients with non Q-wave ACSs between the two treatment groups (2.8% and 2.7%, respectively) (Fig. 1). During the hospitalization, cardiovascular mortality was P similar among patients with Q-wave MI who underwent PTCA or CABG (5.6% and 5.9%, respectively), but among patients with non Q-wave ACSs, it was significantly higher in patients who underwent CABG in comparison with PTCA (4.6% vs. 0.5%, P<0.01). In-hospital mortality among patients with Q-wave MI was significantly increased due to deaths of patients admitted to the Clinic in severe condition (63 patients had cardiogenic shock during hospitalization, and 28 of them died). The data of 1161 patients (of the 1165 survivors after ACSs) were available for analysis at one year. Cardiovascular death during the posthospitalization period occurred in 44 patients (3.8%): in 19 patients with Q-wave MI and in 25 patients with non Q-wave ACSs. There was no significant difference in cardiovascular mortality among patients with Q-wave MI and those with non Q-wave ACSs (3.8% and 3.8%, respectively), while the comparison of the MR and pharmacotherapy groups showed significantly higher cardiovascular mortality in patients treated with medications only both in patients with Q-wave MI and non Q-wave ACSs (P<0.05) (Fig. 2). Posthospitalization cardiovascular mortality after PTCA and CABG did not differ significantly among patients with Q-wave MI (2.4% and 2.9%, respectively; P>0.05) and non Q-wave ACSs (0.5% and 2.2%, respectively; P>0.05). Using univariate logistic regression analysis, 20 variables significantly associated with cardiovascular mortality during one-year period were selected. Both methods PTCA and CABG had a prognostic value for the estimation of cardiovascular mortality (unadjusted OR, 0.329; 95% CI, 0.2 to 0.5; Cardiovascular Mortality, % n= * Myocardial revascularization Pharmacotherapy 5.7* Cardiovascular Mortality, % n= * 9.5* Myocardial revascularization Pharmacotherapy 1.4** 7.7** Q-Wave MI Non-Q-Wave ACS Q-Wave MI Non-Q-Wave ACS Fig. 1. In-hospital cardiovascular mortality regarding different treatment strategies *P<0.05, comparing patients with Q-wave myocardial infarction (MI) who underwent myocardial revascularization with those who received pharmacotherapy. Fig. 2. Posthospitalization cardiovascular mortality regarding different treatment strategies during hospitalization *P<0.05, comparing patients with Q-wave myocardial infarction (MI) who underwent myocardial revascularization with those who received pharmacotherapy; **P<0.01, comparing patients with non Q-wave MI who underwent myocardial revascularization with those who received pharmacotherapy.

5 The Impact of Myocardial Revascularization on Cardiovascular Mortality 309 Table 4. The Risk of Cardiovascular Death During a One-Year Period in Patients With Acute Coronary Syndromes Variable PTCA* CABG* Only pharmacotherapy** Q-wave MI Age >65 years Renal failure Acute heart failure (Killip class 3 4) Ventricular fibrillation Mitral valve insufficiency 2 degree Unadjusted Odds Ratio (95% CI) ( ) ( ) 2.30 ( ) ( ) ( ) ( ) ( ) ( ) 3.4 ( ) P Adjusted Odds Ratio (95% CI) ( ) ( ) 2.51 ( ) ( ) ( ) ( ) ( ) ( ) 2.36 ( ) CI, confidence interval; MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting. *Reference category, only pharmacotherapy; **reference category, PTCA and CABG. P P, and unadjusted OR, 0.504; 95% CI, 0.34 to 0.82; P=0.027, respectively) (Table 4). Multivariate logistic regression analysis revealed that age, Q-wave MI, mitral valve insufficiency, renal failure, acute heart failure, in-hospital revascularization remained significantly associated with cardiovascular mortality. PTCA and CABG independently reduced the risk of cardiovascular death within one year (adjusted OR, 0.304; 95% CI, 0.18 to 0.53; P, and adjusted OR, 0.540, 95% CI, 0.32 to 0.90; P=0.018, respectively) (Table 4). The Kaplan-Meier estimates of overall one-year cardiovascular mortality irrespectively of the ACS type showed that the probability of death was significantly higher in patients who received pharmacological treatment during their hospitalization period than those who underwent PTCA or CABG (14.3% vs. 5.4% and 7.8%, P<0.05) (Fig. 3). Discussion Our study analyzed the rate of MR procedures among 1226 consecutive patients with ACSs treated in 2005 in a single cardiology center, and the impact of these procedures on one-year cardiovascular mortality. During hospitalization, MR procedures were applied in approximately two-thirds of the patients studied. According to the published articles, during the last decade, a considerable increase in the rate of MR procedures applied within the early period of ACSs has been reported. According to the data of the Canadian Acute Coronary Syndromes Registry (2004), MR was performed in 23.5% to 19.5% of patients with ACSs, according to the GRACE study (2005), the rate of performed MR procedures was 65% and 37% in patients with ST-segment elevation and non ST-segment elevation ACSs, respectively, and according to the Australian Registry (2008), early invasive treatment was applied in 70.0% to 89.7% of patients with MI and in 44.8% of patients with UAP (6 8). The published studies provide markedly varying frequencies of CABG procedures performed during the inpatient period (2.8% to 21%) (9 12). Probability of Cardiovascular Death Pharmacotherapy 3 CABG 2 PTCA Duration of Follow-up, Days Fig. 3. The probability of cardiovascular death during one year after acute coronary syndromes regarding treatment strategies applied during hospitalization Log rank test: 1-3 (χ 2 =15.8), P; 2-3 (χ 2 =5.9), P=0.015; 1-2 (χ 2 =1.84), P= In our study, the frequency of MR procedures for ACS was considerably higher as compared with the findings of other studies: MR was performed in 81.1% of cases with Q-wave MI, in 70.2% of cases with non Q-wave MI, and in more than half (56%) of patients with UAP. The guidelines of the European Association of Management of Acute Coronary Syndrome (2007) indicate that in case of ACSs, in-hospital mortality reaches 7% to 5%; in cases of ST-elevation MI, this mortality may be significantly reduced by applying PTCA (13). According to different published data, in-hospital or 30-day mortality following PTCA reaches 3.1% to 8.5%, and the impact of this procedure depends on the duration of the symptoms before PTCA (14 16). If PTCA is performed within 2 hours from the onset of the symptoms, in-hospital mortality accounts for 1.3% to 2.7%, and if later 4.6% to 6.2% (17 19). Early myocardial reperfusion is associated not only with better survival, but also with higher probability of the normalization of the

6 310 Dalia Lukšienė, Irena Milvidaitė, Rimvydas Šlapikas, et al. left ventricular function and lower rate of cardiac events during the posthospitalization period (20, 21). According to our findings, more than twothirds of patients with Q-wave MI underwent PTCA within the first 12 hours from the onset, and their in-hospital mortality was 5.6%. According to the data of the European Heart Survey, 30-day mortality in patients with ST-segment elevation MI was higher after CABG (8.0%) than PTCA (4.0%) or pharmacotherapy (5.0%) (9). Other authors indicate lower in-hospital mortality (1.1% to 3.7%) following CABG in patients with ST-segment elevation MI, but the data are scarce and incomparable (10, 11). In our study, in-hospital mortality following CABG among patients with Q- wave MI was 5.9%. Significantly higher in-hospital mortality (16.7%) among patients with Q-wave MI and treated with medications alone might have been influenced by a complicated clinical situation when patients were in cardiogenic shock on admission, and MR was either not performed or ineffective. In our study, posthospitalization cardiovascular mortality among patients with Q-wave MI who underwent MR was similar to that indicated in literature (22 24): cardiac death occurred in 2.4% to 2.9% of patients after MR procedure, and in 9.5% of patients who received pharmacological treatment alone. It is noteworthy that when comparing cardiovascular mortality in patients with Q-wave MI (our findings) and patients with ST-segment elevation MI (literature data), one should keep in mind that these are not equivalent forms of MI. It has been indicated that if PTCA is performed within 2 hours from the onset of ST-segment elevation ACSs, MI area is reduced by 31%, in 15% of MI cases, Q wave does not emerge, and thus the percentage of patients with Q-wave MI becomes lower than the number of patients with ST-segment elevation MI (25, 26). This has also been confirmed by the data of the Canadian ACS Registry: 21.3% of patients treated for non Q-wave MI were hospitalized for ST-segment elevation ACSs (6). According to the literature, MR performed in patients with non ST-segment elevation ACSs has no significant impact on survival during the hospitalization period: in-hospital mortality reached 2% to 3% irrespectively of whether the patients were treated with PTCA, CABG, or pharmacotherapy (9). During the posthospitalization period, the impact of MR on the survival of these patients is controversial. According to the European Heart Survey, the total one-year mortality in patients with non Q-wave ACSs following PTCA and CABG was 4% and following pharmacotherapy 7% (9). According to the VANQWISH study, there was no significant difference in the 23-month mortality between the invasive and the pharmacological treatment groups (17% and 14%, respectively) (27). Other authors who analyzed a number of randomized studies did not find any significant difference in the survival of patients routinely and selectively treated using invasive techniques either (28). Bavry et al. performed a meta-analysis of 5 randomized studies and reported that the application of early invasive treatment in patients with non ST-segment elevation ACSs reduced the overall 12-month and 24-month mortality by 20% to 23% as compared with that in the conservative treatment group (29). Our observational findings are in agreement with those presented in literature. There was no significant difference in in-hospital mortality among patients with non-q-wave ACSs between the MR and conservatively treated groups (2.8% and 2.7%, respectively). However, MR performed during hospitalization significantly reduced one-year mortality compared with mortality observed in patients treated with medications alone (1.4% and 7.7%, respectively; P). On the other hand, it is noteworthy that the condition of the patients who received conservative treatment was worse, and the EuroSCORE risk score in this group was significantly higher. Evaluation of the impact of MR on the overall (in-hospital and posthospitalization) cardiovascular mortality adjusting for clinical risk variables showed that MR had a positive impact on disease prognosis as compared with pharmacological treatment. Conclusions Percutaneous transluminal coronary angioplasty performed during hospitalization and coronary artery bypass grafting within 60 days after acute coronary syndromes were significantly associated with the reduction of cardiovascular mortality within one-year period independently of clinical risk variables (adjusted OR, 0.304; 95% CI, 0.18 to 0.53; P and adjusted OR, 0.540; 95% CI, 0.32 to 0.90; P=0.018). In the assurance of timely invasive treatment, greater attention should be focused on the early transfer of patients with acute coronary syndromes to a tertiary cardiac clinic as well as on education of the population about the importance of early seeking for medical assistance in the presence of acute myocardial ischemia. Statement of Conflict of Interest The authors state no conflict of interest.

7 The Impact of Myocardial Revascularization on Cardiovascular Mortality 311 Miokardo revaskulizacijos, atliktos ištikus ūminiams išeminiams sindromams, įtaka mirties dažnumui vienerių metų laikotarpiu Dalia Lukšienė 1, Irena Milvidaitė 1, 2, Rimvydas Šlapikas 2, Gediminas Jaruševičius 2, Adakrius Siudikas 3, Jonė Venclovienė 1, Remigijus Žaliūnas 2 1 Lietuvos sveikatos mokslų universiteto Medicinos akademijos Kardiologijos institutas, 2 Lietuvos sveikatos mokslų universiteto Medicinos akademijos Kardiologijos klinika, 3 Lietuvos sveikatos mokslų universiteto Medicinos akademijos Širdies, krūtinės ir kraujagyslių chirurgijos klinika Raktažodžiai: ūminiai išeminiai sindromai, miokardo revaskulizacija, vienerių metų mirštamumas. Santrauka. Tyrimo tikslas. Stebėsenos studijos metu vertinti miokardo revaskulizacijos, atliktos ištikus ūminiams išeminiams sindromams, įtaką mirštamumui vienerių metų laikotarpiu. Tyrimo medžiaga ir metodai. Vienerių metų laikotarpiu stebėti 1226 ligoniai, 2005 m. gydyti Lietuvos sveikatos mokslų universiteto ligoninės (tuometinių Kauno medicinos universiteto klinikų) Kardiologijos klinikoje, kuriems ūminio išeminio sindromo metu rastos didelio laipsnio ( 70 proc.) vainikinių arterijų stenozės. Vienerių metų mirštamumo ryšys su miokardo revaskulizacija vertintas taikant daugiaveiksnę logistinę regresiją. Mirštamumas vertintas pagal Kaplan-Mėjerio kreives. Rezultatai. Q bangos miokardo infarktu sirgo 540 ligonių, be Q bangos ūminiais išeminiais sindromais 686. Stacionarinio gydymo laikotarpiu perkutaninė transliuminalinė vainikinių arterijų angioplastika atlikta 496 ligoniams, 60 dienų laikotarpiu po ūminių išeminių sindromų vainikinių arterijų ir aortos jungties operacija atlikta 373 ir tik medikamentais gydyti 357 ligoniai. Stebėsenos laikotarpiu užregistruota 105 mirties atvejai. Vienerių metų laikotarpiu mirties dažnumas buvo žymiai mažesnis patyrusiųjų perkutaninę vainikinių arterijų angioplastiką arba vainikinių arterijų aortos jungties operaciją, nei vien medikamentais gydytų ligonių (5,4 ir 7,8 proc., ir 14,3 proc. atitinkamai, p<0,05). Naudojant daugiaveiksnę logistinę regresiją, nustatyta abiejų miokardo revaskulizacijos metodų nepriklausoma nuo kitų informatyvių klinikinių žymenų įtaka mirties dažniui vienerių metų laikotarpiu (perkutaninės angioplastikos standartizuotas šansų santykis - 0,304, 95% PI 0,18-0,53, p<0,001, vainikinių arterijų aortos jungties operacijos 0,540, 95% PI 0,32-0,90, p=0,018). Išvada. Miokardo revaskulizacija, atlikta ištikus ūminiams išeminiams sindromams, nepriklausomai nuo in formatyvių klinikinių žymenų reikšmingai mažina mirties nuo išeminių sindromų riziką vienerių metų laikotarpiu. References 1. Lemesle G, De Labriolle A, Bonello L, Torguson R, Kaneshige K, Xue Z, et al. Incidence, predictors, and outcome of new, subsequent lesions treated with percutaneous coronary intervention in patients presenting with myocardial infarction. Am J Cardiol 2009;103: Beck ChA, Eisenberg MJ, Pilote L. Invasive versus noninvasive management of ST-elevation acute myocardial infarction: a review of clinical trials and observational studies. Am Heart J 2005;149: Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias. JAMA 2007;297: Hirsch A, Windhausen F, Tijssen JGP, Oude Ophuis AJM, Van der Giessen WJ, Van der Zee PM, et al. Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-st-segment elevation acute coronary syndrome: the problem of treatment selection bias. Eur Heart J 2009;30: Mehta SR, Cannon ChP, Fox KAA, Wallentin L, Boden WE, Spacek R, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes. JAMA 2005;293: Yan AT, Tan M, Fitchett D, Chow Ch-M, Fowlis RA, McAvinue TG, et al. One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry). Am J Cardiol 2004;94: Carruthers KF, Dabbous OH, Flather MD, Starkey I, Jacob A, Macleod D, et al. Contemporary management of acute coronary syndromes: does the practice match the evidence? The global registry of acute coronary events (GRACE). Heart 2005;91(3): Chew DP, Amerena JV, Coverdale SG, Rankin JM, Astley CM, Soman A, et al. Invasive management and late clinical outcomes in contemporary Australian management of acute coronary syndromes: observations from the ACACIA registry. MJA 2008;188(12): Lenzen MJ, Boersma E, Bertrand ME, Maier W, Moris C, Piscione F, et al. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J 2005;28: Solodky A, Behar S, Boyko V, Battler A, Hasdai D. The outcome of coronary artery bypass grafting surgery among patients hospitalized with acute coronary syndrome: the Euro Heart Survey of acute coronary syndrome experience. Cardiology 2005;103(1): Monteiro P; Portuguese Registry on Acute Coronary Syndromes. Impact of early coronary artery bypass graft in an unselected acute coronary syndrome patient population. Circulation 2006;114(Suppl I):I Cequier A. The MASCARA registry reveals the true nature of acute coronary syndromes treatment in Spain. Rev Esp Cardiol 2008;61: Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, Ardissino

8 312 Dalia Lukšienė, Irena Milvidaitė, Rimvydas Šlapikas, et al. D, Boersma E, Budaj A, et al. Guidelines for the diagnosis and treatment of non-st-segment elevation acute coronary syndromes. Eur Heart J 2007;28: Addala S, Grines CL, Dixon SR, Stone GW, Boura JA, Ochoa AB, et al. Predicting mortality in patients with STelevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI Risk Score). Am J Cardiol 2004;93: Steg PG, Francois L, Iung B, Himbert D, Aubry P, Charler P, et al. Long-term clinical outcomes after rescue angioplasty are not different from those of successful thrombolysis for acute myocardial infarction. Eur Heart J 2005;26: Boersma E, Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006;27: Patel TN, Bavry AA, Kumbhani DJ, Ellis SG. A meta-analysis of randomized trials of rescue percutaneous coronary intervention after failed fibrinolysis. Am J Cardiol 2006; 97: Shavelle DM, Rasouli ML, Frederick P, Gibson CM, French WJ; National Registry of Myocardial Infarction Investigators. Outcome in patients transferred for percutaneous coronary intervention (a national registry of myocardial infarction 2/3/4 analysis). Am J Cardiol 2005;96: Schömig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset. JAMA 2005;293: Funaro S, La Torre G, Madona M, Galiuto L, Scara A, Labbadia A, et al. Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study. Eur Heart J 2009;30: De Luca G, Ernst N, Zijlstra F, van t Hof AW, Hoorntje JC, Dambrink JH, et al. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2004;43: Mehta RH, O Neill WW, Harjai KJ, Cox DA, Brodie BR, Boura J, et al. Prediction of one-year mortality among 30- day survivors after primary percutaneous coronary interventions. Am J Cardiol 2006;97: Busk M, Maeng M, Kristensen SD, Thuesen L, Krusell LR, Mortensen LS, et al. Timing, causes, and predictors of death after three years follow-up in the Danish Multicenter Randomized Study of Fibrinolysis versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) trial. Am J Cardiol 2009;104: Held C, Tornvall P, Stenestrand U. Effects of revascularization within 14 days of hospital admission due to acute coronary syndrome on 1-year mortality in patients with previous coronary artery bypass graft surgery. Eur Heart J 2007;28(3): Busk M, Kaltoft A, Nielsen SS, Bøttcher M, Rehling M, Thuesen L, et al. Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for <12 h vs h. Eur Heart J 2009;30: Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, et al. Hospital delays in reperfusion for STelevation myocardial infarction. Implications when selecting a reperfusion strategy. Circulation 2006;114: Boden WE, O Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, et al. Outcomes in patients with acute non-q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial investigators. N Engl J Med 1998;338: Qayyum R, Khalid R, Adomaityte J, Papadakos SP, Messineo FC. Systematic review: comparing routine and selective invasive strategies for the acute coronary syndrome. Ann Intern Med 2008;148: Bavry AA, Kumbhani DJ, Quiroz R, Ramchandani SR, Kenchaiah S, Antman EM. Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-st-segment elevation acute coronary syndromes: a meta-analysis and review of the literature. Am J Cardiol 2004;93: Received 10 March 2010, accepted 22 June 2011 Straipsnis gautas , priimtas